Fed. Circ. Strikes Down More Myriad Cancer Test Patents


William Gaede led the McDermott team that included Eric Hagen, James Hill, M. Miller Baker, Daniel Greene, and John Low in successfully arguing the appeal of Ambry Genetics before the Federal Circuit. The court’s ruling that three Myriad Genetics Inc. breast cancer test patents are invalid was a win for Ambry Genetics, which makes rival breast cancer tests that Myriad had accused of infringement.